← All trials
NCT04401059
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 20, 2020
- Primary completion
- Jun 14, 2023
- Completion date
- Dec 31, 2023
- First posted
- May 25, 2020
- Last posted
- May 25, 2020
- Enrollment
- 468
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hangzhou Normal UniversityLead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Hangzhou Normal UniversitySponsor investigator
- LinkDoc Technology (Beijing) Co. Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.